Navigation Links
Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
Date:11/13/2007

mersen was well tolerated throughout the study.

Further, Isis reported results of an integrated safety analysis including data from more than 250 subjects treated with mipomersen in Phase 1 and Phase 2 studies. This analysis demonstrates that mipomersen has been well tolerated and that treatment with mipomersen did not result in evidence of liver toxicity. Among all subjects who received mipomersen, there were no instances of transaminase (ALT) elevations associated with two-fold increase in bilirubin or any other signs or symptoms of liver dysfunction. While on treatment, 3% of subjects treated with placebo and 3% of subjects treated with 200 mg/week mipomersen experienced ALT elevations of 150-250 IU/L. During the entire study periods, including dosing plus 90 day follow up, 5% and 7% of subjects treated with placebo or 200 mg/week of mipomersen, respectively, experienced ALT elevations of 150-250 IU/L. The most common adverse event was mild to moderate injection site reactions.

According to Jeffrey Jonas, M.D., Executive Vice President, Isis Pharmaceuticals, "Our clinical experience continues to demonstrate the lipid-lowering activity of mipomersen, which has been equally effective across multiple patient populations both as a single agent and in combination with lipid-lowering therapies. Furthermore, mipomersen's lipid-lowering effects have been highly predictable. As we expected, extending treatment from five to 13 weeks results in further lipid lowering, increasing LDL-C reductions from 30% to 48%.

"In addition, we have now dosed over 250 subjects with mipomersen and are able to present an extensive integrated safety summary. We have explored a full dose range for mipomersen as a single agent and in combination with moderate to maximal lipid-lowering therapies, and we have exposed subjects to aggressive loading and induction schedules. Mipomersen continues to display an attractive safety profile. The primary adverse event in our studies has b
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
(Date:9/17/2014)... Sept. 17, 2014  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that agreement has been reached with the ... design of a pivotal, Phase 3 clinical trial ... treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... Massachusetts , 17. September 2014 ... HOLX ), hat heute die ... zur präanalytischen Probenverarbeitung, in Europa bekannt ... gekennzeichnete, vollautomatisierte Universalplattform zur Vereinfachung der ... dass ineffiziente und fehlerbehaftete Arbeitsschritte bei ...
Breaking Medicine Technology:Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3
... Inspiration Biopharmaceuticals, Inc. (Inspiration), the only ... of new treatment options for people with hemophilia, is ... as Chief Executive Officer. Mr. Butler replaces Michael Griffith, ... Officer and is retaining the title of President at ...
... 11, 2011 Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ... financial results on Tuesday, October 25, 2011 after the close ... conference call and slide presentation via webcast on Tuesday, October ... to discuss results and highlights of the third quarter, as ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer 2Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer 3Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011 2
(Date:9/17/2014)... 17, 2014 With the development ... functions of adjusting human body physiology, preventing diseases, ... popularity with a variety of specific populations. In ... China reached RMB187.4 billion, up 12.0% year on ... , China's health product industry is composed of ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 U.S. ... hospitals in the country, and three mesothelioma treatment ... treatment facilities, the mesothelioma law firm Baron ... Cancer Center, University of Texas MD Anderson Cancer ... by the publication. ( http://health.usnews.com/best-hospitals/rankings/cancer ) , U.S. ...
(Date:9/17/2014)... FL (PRWEB) September 17, 2014 ... with Ed Begley, Jr., scheduled to broadcast on ... via Discovery Channel. , In this episode, Innovations ... House of Freedom’s mission to provide each client ... and spiritual well being; using the principles of ...
(Date:9/17/2014)... 2014 Experienced dress company, Discount-Dress.com, announces ... selection of trendy black bridesmaid dresses. Furthermore, the company ... beautiful bridesmaid outfits. Readers can view more ... Discount-Dress.com is a famous brand of special occasion ... as well as revamped old editions, the supplier has ...
(Date:9/17/2014)... Headquartered in Baltimore, Maryland, Therapy Pets Unlimited ... , “The past two weeks have been amazing,” ... over 400 evaluators in 46 states, and we’re still ... and South Dakota and Vermont. And from there, we ... can visit.” , TPU provides one-of-a-kind treatment to facilities ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 2Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 3Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Discount-Dress.com’s Top Designers Are Now Busy Making Its New Black Bridesmaid Dresses 2Health News:Therapy Pets Unlimited is Expanding 2Health News:Therapy Pets Unlimited is Expanding 3
... of a molecular community in brain cells of mammals ... of new drugs. Researchers from Mount Sinai School // ... latest issue of journal Science. , ,The study ... within these communities enable groups of molecules and proteins ...
... the spice turmeric its yellow color, has come under ... its cancer-fighting abilities // . ,Researchers say ... block a key protein associated with esophageal cancer, known ... “ a shot in the arm for research,” ...
... time for meditation, yoga or even a trip to ... very compact these days. Thanks to the Chocolate-coated stress ... soon. ,The chocolate-like product comprises various nutraceutical herbs ... been developed by National Botanical Research Institute (NBRI), Lucknow., ...
... A protein that protects the body from tissue damage has ... protein helps the body's healthy cells survive the effects of ... found to encourage the growth of tumors in mice following ... urethane, a lung-specific carcinogen, on two sets of mice, which ...
... Mark A. Fishel, M.D., from the University of Washington, ... increase in Alzheimer’s disease. Moderately elevated levels of ... // in plasma and in cerebrospinal fluid and these ... was conducted in 16 healthy older adults ranging in ...
... from UCLA had found out that a deficient gene ... enzyme in the vision cycle that causes congenital blindness ... disease // called Leber congenital amaurosis is published in ... suggest that replacement of RPE65, which is lacking in ...
Cached Medicine News:Health News:The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties 2Health News:Enzyme Responsible For Congenital Blindness 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: